Abstract
Small bowel (SBNETs) and pancreatic neuroendocrine tumors (PNETs) often present with liver metastases. Although liver biopsy establishes a neuroendocrine diagnosis, the primary tumor site is frequently unknown without exploratory surgery. Gene expression differences in metastases may distinguish primary SBNETs and PNETs. This study sought to determine expression differences of four genes in neuroendocrine metastases and to create a gene expression algorithm to distinguish the primary site. Nodal and liver metastases from SBNETs and PNETs (n = 136) were collected at surgery under an Institutional Review Board-approved protocol. Quantitative PCR measured expression of bombesin-like receptor-3, opioid receptor kappa-1, oxytocin receptor, and secretin receptor in metastases. Logistic regression models defined an algorithm predicting the primary tumor site. Models were developed on a training set of 21 nodal metastases and performance was validated on an independent set of nodal and liver metastases. Expression of all four genes was significantly different in SBNET compared to PNET metastases. The optimal model employed expression of bombesin-like receptor-3 and opioid receptor kappa-1. When these genes did not amplify, the algorithm used oxytocin receptor and secretin receptor expression, which allowed classification of all 136 metastases with 94.1 % accuracy. In the independent liver metastasis validation set, 52/56 (92.9 %) were correctly classified. Positive predictive values were 92.5 % for SBNETs and 93.8 % for PNETs. This validated algorithm accurately distinguishes SBNET and PNET metastases based on their expression of four genes. High accuracy in liver metastases demonstrates applicability to the clinical setting. Studies assessing this algorithm’s utility in prospective clinical decision-making are warranted.
Similar content being viewed by others
Abbreviations
- SBNETs:
-
Small bowel neuroendocrine tumors
- PNETs:
-
Pancreatic neuroendocrine tumors
- NETs:
-
Neuroendocrine tumors
- mTOR:
-
Mammalian target of rapamycin
- IHC:
-
Immunohistochemistry
- OXTR:
-
Oxytocin receptor
- SCTR:
-
Secretin receptor
- GIPR:
-
Gastric inhibitory polypeptide receptor
- BRS3:
-
Bombesin-like receptor-3
- OPRK1:
-
Opioid receptor kappa-1
- Ct:
-
Threshold cycles
- GAPDH:
-
Glyceraldehyde-3-phosphate dehydrogenase
- POLR2A:
-
Polymerase (RNA) II polypeptide A
- dCT:
-
Delta threshold cycles
- PFS:
-
Progression-free survival
- OS:
-
Overall survival
- CDX2:
-
Caudal type homeobox 2
- ISL1:
-
Insulin gene enhancer binding protein 1
- PR:
-
Progesterone receptor
- PAX6:
-
Paired box gene 6
- IQR:
-
Interquartile range
- CI:
-
Confidence interval
- PPV:
-
Positive predictive value
References
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072. doi:10.1200/JCO.2007.15.4377
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61–72. doi:10.1016/S1470-2045(07)70410-2
Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK (2010) Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 145(3):276–280. doi:10.1001/archsurg.2010.10
Oberg K, Knigge U, Kwekkeboom D, Perren A (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii124–130. doi:10.1093/annonc/mds295
Dahdaleh FS, Lorenzen A, Rajput M, Carr JC, Liao J, Menda Y, O’Dorisio TM, Howe JR (2013) The value of preoperative imaging in small bowel neuroendocrine tumors. Ann Surg Oncol 20(6):1912–1917. doi:10.1245/s10434-012-2836-y
Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37(1):67–77. doi:10.1007/s00259-009-1205-y
Bartlett EK, Roses RE, Gupta M, Shah PK, Shah KK, Zaheer S, Wachtel H, Kelz RR, Karakousis GC, Fraker DL (2013) Surgery for metastatic neuroendocrine tumors with occult primaries. J Surg Res 184(1):221–227. doi:10.1016/j.jss.2013.04.008
Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663. doi:10.1200/JCO.2009.22.8510
Korse CM, Taal BG, van Velthuysen ML, Visser O (2013) Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 49(8):1975–1983. doi:10.1016/j.ejca.2012.12.022
Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37. doi:10.1016/S1072-7515(03)00230-8
Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Ferrero A, Schulick RD, Choti MA, Mentha G, Strub J, Bauer TW, Adams RB, Aldrighetti L, Capussotti L, Pawlik TM (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17(12):3129–3136. doi:10.1245/s10434-010-1154-5
Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Horsch D, O’Dorisio MS, O’Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40(5):800–816. doi:10.1007/s00259-012-2330-6
Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF (2006) Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 140 (6):891–897; discussion 897–898. doi:10.1016/j.surg.2006.07.033
Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF (2009) Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 115(4):741–751. doi:10.1002/cncr.24065
Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M (2011) Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology 93(4):223–229. doi:10.1159/000324770
Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M (2012) Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg 99(11):1480–1486. doi:10.1002/bjs.8842
Strosberg JR (2013) Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current approaches and future options. Endocr Pract 20(2):167–175. doi:10.4158/EP13262.RA
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523. doi:10.1056/NEJMoa1009290
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513. doi:10.1056/NEJMoa1003825
Oberg K, Casanovas O, Castano JP, Chung D, Delle Fave G, Denefle P, Harris P, Khan MS, Kulke MH, Scarpa A, Tang LH, Wiedenmann B (2013) Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res 19(11):2842–2849. doi:10.1158/1078-0432.CCR-12-3458
Ganetsky A, Bhatt V (2012) Gastroenteropancreatic neuroendocrine tumors: update on therapeutics. Ann Pharmacother 46(6):851–862. doi:10.1345/aph.1Q729
Sherman SK, Howe JR (2013) Translational research in endocrine surgery. Surg Oncol Clin N Am 22(4):857–884. doi:10.1016/j.soc.2013.06.012
Bellizzi AM (2013) Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol 20(5):285–314. doi:10.1097/PAP.0b013e3182a2dc67
Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D (2012) Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol 25(6):893–901. doi:10.1038/modpathol.2012.34
Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Huang VJ, Erlander MG, Brachtel EF, Dry SM (2013) A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors. Mod Pathol. doi:10.1038/modpathol.2013.105
Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Singh V, Carey B, Erlander MG, Highsmith WE, Dry SM, Brachtel EF (2012) Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res 18(14):3952–3960. doi:10.1158/1078-0432.CCR-12-0920
Posorski N, Kaemmerer D, Ernst G, Grabowski P, Hoersch D, Hommann M, von Eggeling F (2011) Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases. Clin Exp Metastasis 28(7):637–647. doi:10.1007/s10585-011-9397-5
Carr JC, Boese EA, Spanheimer PM, Dahdaleh FS, Martin M, Calva D, Schafer B, Thole DM, Braun T, O’Dorisio TM, O’Dorisio MS, Howe JR (2012) Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling. Surgery 152(6):998–1007. doi:10.1016/j.surg.2012.08.040
Carr JC, Sherman SK, Wang D, Dahdaleh FS, Bellizzi AM, O’Dorisio MS, O’Dorisio TM, Howe JR (2013) Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors. Ann Surg Oncol 20(Suppl 3):739–746. doi:10.1245/s10434-013-3318-6
Sherman SK, Carr JC, Wang D, O’Dorisio MS, O’Dorisio TM, Howe JR (2013) Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. Surgery 154(6):1206–1214. doi:10.1016/j.surg.2013.04.052
Dahdaleh FS, Calva-Cerqueira D, Carr JC, Liao J, Mezhir JJ, O’Dorisio TM, Howe JR (2012) Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution. Ann Surg Oncol 19(3):966–972. doi:10.1245/s10434-011-1997-4
Begum N, Hubold C, Buchmann I, Thorns C, Bouchard R, Lubienski A, Schloricke E, Zimmermann M, Lehnert H, Bruch HP, Burk CG (2013) Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary—a plea for open exploration. Zentralbl Chir. doi:10.1055/s-0032-1327962
Taner T, Atwell TD, Zhang L, Oberg TN, Harmsen WS, Slettedahl SW, Kendrick ML, Nagorney DM, Que FG (2013) Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB (Oxford) 15(3):190–195. doi:10.1111/j.1477-2574.2012.00528.x
Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, Granberg D, Eriksson B, Akerstrom G, Hellman P (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32(5):930–938. doi:10.1007/s00268-008-9510-3
Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O’Connor JM, Salazar R, Taal BG, Vullierme MP, O’Toole D (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 95(2):120–134. doi:10.1159/000335587
Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plockinger U, Salazar R, Grossman A (2012) ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95(2):135–156. doi:10.1159/000335629
Kuo EJ, Salem RR (2013) Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol 20(9):2815–2821. doi:10.1245/s10434-013-3005-7
Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, Levy MJ, Huebner M (2012) Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 152(6):965–974. doi:10.1016/j.surg.2012.08.038
Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2):157–176. doi:10.1159/000335597
Stashek KM, Czeczok TW, Bellizzi AM (2014) Extensive evaluation of immunohistochemistry to assign site of origin in well-differentiated neuroendocrine tumors: a study of 10 markers in 265 tumors. Mod Pathol 27(Suppl 2):160A
Acknowledgments
We gratefully acknowledge our patients for participating in this research. Supported by NIH 5T32#CA148062-03 (SKS, JEM, JCC)
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sherman, S.K., Maxwell, J.E., Carr, J.C. et al. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clin Exp Metastasis 31, 935–944 (2014). https://doi.org/10.1007/s10585-014-9681-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-014-9681-2